Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 23
Encontrada(s) 1 página(s)

Digibug. Repositorio Institucional de la Universidad de Granada
Publication Artículo científico (JournalArticle)

BAFF, APRIL and BAFFR on the pathogenesis of Immunoglobulin‑A vasculitis

  • Prieto‑Peña, Diana
  • Ortego Centeno, Norberto
We are indebted to the patients and healthy controls for their essential collaboration to this study. We also thank the National DNA Bank Repository (Salamanca) for supplying part of the control samples. This study was supported by European Union FEDER funds and `Fondo de Investigaciones Sanitarias´ (grant PI18/00042) from ‘Instituto de Salud Carlos III’ (ISCIII, Health Ministry, Spain). DP-P is a recipient of a Río Hortega programme fellowship from the ISCIII, co-funded by the European Social Fund (ESF, `Investing in your future´) (grant number CM20/00006). SR-M is supported by funds of the RETICS Program (RD16/0012/0009) (ISCIII, co-funded by the European Regional Development Fund (ERDF)). VP-C is supported by a pre-doctoral grant from IDIVAL (PREVAL 18/01). BA-M is a recipient of a `López Albo´ Post-Residency Programme funded by Servicio Cántabro de Salud. LL-G is supported by funds from IDIVAL (INNVAL20/06). OG is staff personnel of Xunta de Galicia (Servizo Galego de Saude (SERGAS)) through a research-staff stabilization contract (ISCIII/SERGAS) and his work is funded by ISCIII and the European Union FEDER fund (grant numbers RD16/0012/0014 (RIER) and PI17/00409). He is beneficiary of project funds from the Research Executive Agency (REA) of the European Union in the framework of MSCA-RISE Action of the H2020 Programme, project 734899—Olive-Net. RL-M is a recipient of a Miguel Servet type I programme fellowship from the ISCIII, co-funded by ESF (`Investing in your future´) (grant number CP16/00033)., Supplementary Information The online version contains supplementary material available at https:// doi. org/ 10. 1038/ s41598- 021- 91055-z, BAFF, APRIL and BAFF-R are key proteins involved in the development of B-lymphocytes and autoimmunity. Additionally, BAFF, APRIL and BAFFR polymorphisms were associated with immunemediated conditions, being BAFF GCTGT>A a shared insertion-deletion genetic variant for several autoimmune diseases. Accordingly, we assessed whether BAFF, APRIL and BAFFR represent novel genetic risk factors for Immunoglobulin-A vasculitis (IgAV), a predominantly B-lymphocyte inflammatory condition. BAFF rs374039502, which colocalizes with BAFF GCTGT>A, and two tag variants within APRIL (rs11552708 and rs6608) and BAFFR (rs7290134 and rs77874543) were genotyped in 386 Caucasian IgAV patients and 806 matched healthy controls. No genotypes or alleles differences were observed between IgAV patients and controls when BAFF, APRIL and BAFFR variants were analysed independently. Likewise, no statistically significant differences were found in the genotype and allele frequencies of BAFF, APRIL or BAFFR when IgAV patients were stratified according to the age at disease onset or to the presence/absence of gastrointestinal (GI) or renal manifestations. Similar results were disclosed when APRIL and BAFFR haplotypes were compared between IgAV patients and controls and between IgAV patients stratified according to the clinical characteristics mentioned above. Our results suggest that BAFF, APRIL and BAFFR do not contribute to the genetic network underlying IgAV., European Union FEDER fund RD16/0012/0014, H2020 Programme 734899, Health Ministry, Servicio Cántabro de Salud, Servizo Galego de Saude, European Commission PI18/00042 EC, Research Executive Agency REA, Instituto de Salud Carlos III CP16/00033,PI17/00409 ISCIII, European Social Fund CM20/00006,RD16/0012/0009 ESF, European Regional Development Fund ERDF, Instituto de Investigación Marqués de Valdecilla PREVAL 18/01 IDIVAL, Servicio Gallego de Salud SERGAS
Digibug. Repositorio Institucional de la Universidad de Granada
Publication Artículo científico (JournalArticle)

IgA Vasculitis: Influence of CD40, BLK and BANK1 Gene Polymorphisms

  • Liz, Joao Carlos Batista
  • Márquez, Ana
  • Ortego Centeno, Norberto
  • Martín, Javier
CD40, BLK and BANK1 genes involved in the development and signaling of B-cells are identified as susceptibility loci for numerous inflammatory diseases. Accordingly, we assessed the potential influence of CD40, BLK and BANK1 on the pathogenesis of immunoglobulin-A vasculitis (IgAV), predominantly a B-lymphocyte inflammatory condition. Three genetic variants within CD40 (rs1883832, rs1535045, rs4813003) and BLK (rs2254546, rs2736340, rs2618476) as well as two BANK1 polymorphisms (rs10516487, rs3733197), previously associated with inflammatory diseases, were genotyped in 382 Caucasian patients with IgAV and 955 sex- and ethnically matched healthy controls. No statistically significant differences were observed in the genotype and allele frequencies of CD40, BLK and BANK1 when IgAV patients and healthy controls were compared. Similar results were found when CD40, BLK and BANK1 genotypes or alleles frequencies were compared between patients with IgAV stratified according to the age at disease onset or to the presence/absence of gastrointestinal or renal manifestations. Moreover, no CD40, BLK and BANK1 haplotype differences were disclosed between patients with IgAV and healthy controls and between patients with IgAV stratified according to the clinical characteristics mentioned above. Our findings indicate that CD40, BLK and BANK1 do not contribute to the genetic background of IgAV., European Commission, Instituto de Salud Carlos III" (ISCIII, Health Ministry, Spain) PI18/00042 PI21/00042 Instituto de Salud Carlos III, European Social Fund (ESF) CM20/00006, RICORS Program from ISCIII, European Commission RD21/0002/0025, RETICS Program (ISCIII) RD16/0012/0009, RETICS Program (European Regional Development Fund (ERDF) RD16/0012/0009, European Union FEDER fund RD16/0012/0014 PI17/00409, Research Executive Agency (REA) of the European Union 734899, Miguel Servet type II program fellowship from the ISCIII, ESF ("Investing in your future") CPII21/00004
Digibug. Repositorio Institucional de la Universidad de Granada
Publication Artículo científico (JournalArticle)

Role of the IL33 and IL1RL1 pathway in the pathogenesis of Immunoglobulin A vasculitis

  • Prieto Peña, Diana
  • Sevilla Pérez, Belén
  • Ortego Centeno, Norberto
  • Márquez Ortiz, Ana
  • Martín, Javier
We are indebted to the patients and healthy controls for their essential collaboration to this study. We also thank the National DNA Bank Repository (Salamanca) for supplying part of the control samples. This study was supported by European Union FEDER funds and `Fondo de Investigaciones Sanitarias (Grant PI18/00042) from 'Instituto de Salud Carlos III' (ISCIII, Health Ministry, Spain). DP-P is a recipient of a Rio Hortega programme fellowship from the ISCIII, co-funded by the European Social Fund (ESF, `Investing in your future) (Grant Number CM20/00006). SR-M is supported by funds of the RETICS Program (RD16/0012/0009) (ISCIII, co-funded by the European Regional Development Fund (ERDF)). VP-C is supported by a pre-doctoral grant from IDIVAL (PREVAL 18/01). BA-M is a recipient of a `Lopez Albo Post-Residency Programme funded by Servicio Cantabro de Salud. LL-G is supported by funds from IDIVAL (INNVAL20/06). OG is staff personnel of Xunta de Galicia (Servizo Galego de Saude (SERGAS)) through a research-staff stabilization contract (ISCIII/SERGAS) and his work is funded by ISCIII and the European Union FEDER fund (Grant Numbers RD16/0012/0014 (RIER) and PI17/00409). He is beneficiary of project funds from the Research Executive Agency (REA) of the European Union in the framework of MSCA-RISE Action of the H2020 Programme, project 734899-Olive-Net. RL-M is a recipient of a Miguel Servet type I programme fellowship from the ISCIII, co-funded by ESF (`Investing in your future) (Grant Number CP16/00033)., Cytokines signalling pathway genes are crucial factors of the genetic network underlying the pathogenesis of Immunoglobulin-A vasculitis (IgAV), an inflammatory vascular condition. An influence of the interleukin (IL)33- IL1 receptor like (IL1RL)1 signalling pathway on the increased risk of several immune-mediated diseases has been described. Accordingly, we assessed whether the IL33-IL1RL1 pathway represents a novel genetic risk factor for IgAV. Three tag polymorphisms within IL33 (rs3939286, rs7025417 and rs7044343) and three within IL1RL1 (rs2310173, rs13015714 and rs2058660), that also were previously associated with several inflammatory diseases, were genotyped in 380 Caucasian IgAV patients and 845 matched healthy controls. No genotypes or alleles differences were observed between IgAV patients and controls when IL33 and IL1RL1 variants were analysed independently. Likewise, no statistically significant differences were found in IL33 or IL1RL1 genotype and allele frequencies when IgAV patients were stratified according to the age at disease onset or to the presence/absence of gastrointestinal (GI) or renal manifestations. Similar results were disclosed when IL33 and IL1RL1 haplotypes were compared between IgAV patients and controls and between, European Commission, 'Instituto de Salud Carlos III' (ISCIII, Health Ministry, Spain) PI18/00042 Instituto de Salud Carlos III, European Social Fund (ESF) CM20/00006, RETICS Program (ISCIII) RD16/0012/0009, European Commission IDIVAL 18/01 INNVAL20/06, Servicio Cantabro de Salud, European Union FEDER fund RD16/0012/0014 PI17/00409, European Commission 734899 CP16/00033
Digibug. Repositorio Institucional de la Universidad de Granada
Publication Artículo científico (JournalArticle)

Role of MUC1 rs4072037 polymorphism and serum KL‑6 levels in patients with antisynthetase syndrome

  • López-Mejías, Raquel
  • González-Gay, Miguel A.
  • Ortego Centeno, Norberto
Study partially supported by a grant from Spanish Society of Pulmonology and Thoracic Surgery (SEPAR 474-2017) and from Euronanomed III / Instituto de Salud Carlos III (ISCIII) (AC17/00027) awarded to SC. SR-M is supported by funds of the RETICS Program (RD16/0012/0009) from the ISCIII, co-funded by the European Regional Development Fund. BA-M is recipient of a ‘López Albo’ Post-Residency Programme funded by Servicio Cántabro de Salud. VP-C is supported by a pre-doctoral grant from IDIVAL (PREVAL 18/01). LL-G is supported by funds from IDIVAL (INNVAL 20/06). RP-F is supported by funds of START project (FOREUM18/34). DP-P is a recipient of a Río Hortega programme fellowship from the ISCIII, co-funded by the European Social Fund (ESF, ‘Investing in your future’) (CM20/00006). OG is staff personnel of Xunta de Galicia (Servizo Galego de Saude (SERGAS)) through a research-staff stabilization contract (ISCIII/SERGAS) and his work is funded by ISCIII and the European Union FEDER fund (RD16/0012/0014 (RIER) and PI17/00409). He is beneficiary of project funds from the Research Executive Agency (REA) of the European Union in the framework of MSCA-RISE Action of the H2020 Programme, Project 734899—Olive-Net. RL-M is a recipient of a Miguel Servet type I programme fellowship from the ISCIII, co-funded by the ESF (CP16/00033)., Mucin 1/Krebs von den Lungen-6 (KL-6) is proposed as a serum biomarker of several interstitial lung diseases (ILDs), including connective tissue disorders associated with ILD. However, it has not been studied in a large cohort of Caucasian antisynthetase syndrome (ASSD) patients. Consequently, we assessed the role of MUC1 rs4072037 and serum KL-6 levels as a potential biomarker of ASSD susceptibility and for the differential diagnosis between patients with ILD associated with ASSD (ASSD-ILD +) and idiopathic pulmonary fibrosis (IPF). 168 ASSD patients (149 ASSD-ILD +), 174 IPF patients and 523 healthy controls were genotyped for MUC1 rs4072037 T > C. Serum KL-6 levels were determined in a subgroup of individuals. A significant increase of MUC1 rs4072037 CC genotype and C allele frequencies was observed in ASSD patients compared to healthy controls. Likewise, MUC1 rs4072037 TC and CC genotypes and C allele frequencies were significantly different between ASSD-ILD+ and IPF patients. Additionally, serum KL-6 levels were significantly higher in ASSD patients compared to healthy controls. Nevertheless, no differences in serum KL-6 levels were found between ASSD-ILD+ and IPF patients. Our results suggest that the presence of MUC1 rs4072037 C allele increases the risk of ASSD and it could be a useful genetic biomarker for the differential diagnosis between ASSD-ILD+ and IPF patients., European Union FEDER fund PI17/00409, Servicio Cántabro de Salud, Servizo Galego de Saude, Spanish Society of Pulmonology and Thoracic Surgery SEPAR 474-2017, European Commission EC 734899, CP16/00033, Research Executive Agency, Instituto de Salud Carlos III AC17/00027, CM20/00006, RD16/0012/0009, RD16/0012/0014, European Social Fund, European Regional Development Fund, Foundation for Research in Rheumatology, Instituto de Investigación Marqués de Valdecilla INNVAL 20/06, PREVAL 18/01, Servicio Gallego de Salud, START, Global Change System for Analysis, Research, and Training FOREUM18/34
Minerva. Repositorio Institucional de la Universidad de Santiago de Compostela
Publication Artículo científico (JournalArticle)

Meteorin-like protein plasma levels are associated with worse outcomes in de novo heart failure

  • Anido Varela, Laura
  • Aragón Herrera, Alana
  • González Maestro, Adrián
  • Tilves Bellas, Carlos
  • Tarazón, Estefanía
  • Solé-González, Eduard
  • Martínez-Sellés, Manuel
  • Guerra-Ramos, José María
  • Carrasquer, Anna
  • Morán-Fernández, Laura
  • García-Vega, David
  • Seoane-Blanco, Ana
  • Moure-González, María
  • Seijas-Amigo, Jose
  • Rodríguez Penas, Diego
  • García Seara, Javier
  • Moraña Fernández, Sandra
  • Vázquez-Abuín, Xocas
  • Roselló-Lletí, Esther
  • Portolés, Manuel
  • Eiras Penas, Sonia
  • Agra Bermejo, Rosa María
  • Álvarez Castro, Ezequiel
  • González Juanatey, José Ramón
  • Feijóo Bandín, Sandra
  • Lago Paz, María Francisca
Background and Aims Meteorin-like protein (Metrnl) has been recently suggested as a new adipokine with protective cardiovascular effects. Its circulating levels in patients seem to be associated with heart failure (HF), although with contradictory results. Our aim was to ascertain whether this adipokine could estimate the prognosis of HF in de novo HF (DNHF) patients. Methods Metrnl plasma levels of 400 patients hospitalized with DNHF (55% of patients with HF with reduced ejection fraction, 17.3% HF with mid-range ejection fraction, 27.8% HF with preserved ejection fraction) were measured by enzyme-linked immunosorbent assay. We performed both sex-pooled and sex-specific analyses. A 12-month follow-up was conducted, during which clinical outcomes such as all-cause mortality, cardiovascular death and re-hospitalization due to HF were collected. Results After a 12-month follow up, higher plasma Metrnl levels were associated with an increased risk for all-cause death and cardiovascular death after adjusting by sex, age, LVEF, hypertension, diabetes, ischemic aetiology, chronic renal failure, NT-proBNP and troponin (hazard ratio [HR] = 1.003, 95% confidence interval [CI] = 1.000–1.005; p-value<.05 and HR = 1.004, 95% CI = 1.001–1.007, p-value<.05, respectively). In line with this, DNHF patients with increased levels of circulating Metrnl had a higher number of occurrences of cardiovascular events. Regarding Metrnl associations with parameters implicated in the development and progression of HF, we found that Metrnl circulating levels were positively correlated with age (r = .322, p-value<.0001), NT-proBNP (r = .281, p-value<.0001) and with the renal dysfunction markers urea (r = .322, p-value<.0001) and creatinine (r = .353, p-value<.0001) and higher in women than men (473.7 [385.9–594.0] pg/mL vs. 428.7 [349.1–561.3] pg/mL, p-value<.006). Finally, concerning the subtype of HF, Metrnl plasma levels were higher in HF with preserved ejection fraction. Conclusion Patients with higher Metrnl levels have a worse prognosis in DNHF. Our results reinforce the association of Metrnl plasma levels with HF progression and outcomes.
Minerva. Repositorio Institucional de la Universidad de Santiago de Compostela
Publication Artículo científico (JournalArticle)

Relaxin‑2 plasma levels in atrial fibrillation are linked to inflammation and oxidative stress markers

  • Aragón Herrera, Alana
  • Couselo Seijas, Marinela
  • Feijóo Bandín, Sandra
  • Anido Varela, Laura
  • Moraña Fernández, Sandra
  • Tarazón, Estefanía
  • Roselló-Lletí, Esther
  • Portolés, Manuel
  • Martínez Sande, José Luis
  • García Seara, Javier
  • Álvarez Castro, Ezequiel
  • González Juanatey, José Ramón
  • Rodríguez Mañero, Moisés
  • Eiras Penas, Sonia
  • Lago Paz, María Francisca
Relaxin-2 exerts many favourable cardiovascular effects in pathological circumstances such as atrial fibrillation (AF) and heart failure, but the mechanisms underlying its actions are not completely understood. Since inflammation and fibrosis are pivotal processes in the pathogenesis of AF, our aim was to study the relationship between relaxin-2 plasma levels in left atrium (LA) and peripheral vein with molecules implicated in fibrosis, inflammation and oxidative stress in AF patients, and to evaluate the anti-fibrotic ability of relaxin-2 in normal human atrial cardiac fibroblasts (NHCF-A). Peripheral vein relaxin-2 plasma levels were higher than LA relaxin-2 plasma levels in men while, in women, peripheral vein relaxin-2 levels were increased compared to men. AF patients with higher levels of relaxin-2 exhibited a reduction in H2O2 plasma levels and in mRNA levels of alpha-defensin 3 (DEFA3) and IL-6 in leucocytes from LA plasma. Relaxin-2-in-vitro treatment inhibited NHCF-A migration and decreased mRNA and protein levels of the pro-fibrotic molecule transforming growth factor-β1 (TGF-β1). Our results support an association between relaxin-2 and molecules involved in fibrosis, inflammation and oxidative stress in AF patients, and reinforce an anti-fibrotic protective role of this hormone in NHCF-A; strengthening the relevance of relaxin-2 in AF physiopathology, diagnosis and treatment.
Addi. Archivo Digital para la Docencia y la Investigación
Publication Artículo científico (JournalArticle)

Influence of MUC5B gene on antisynthetase syndrome

  • López Mejías, Raquel
  • Remuzgo Martínez, Sara
  • Genre, Fernanda
  • Pulito Cueto, Verónica
  • Fernández Rozas, Sonia M.
  • Llorca, Javier
  • Iturbe Fernández, David
  • Mora Cuesta, Víctor M.
  • Ortego Centeno, Norberto
  • Pérez Gómez, Nair
  • Mera Varela, Antonio
  • Martínez Barrio, Julia
  • López Longo, Francisco Javier
  • Mijares, Verónica
  • Lera Gómez, Leticia
  • Usetti, María Piedad
  • Laporta, Rosalía
  • Pérez, Virginia
  • De Pablo Gafas, Alicia
  • Alfranca González, María Aránzazu
  • Calvo Alén, Jaime
  • Romero Bueno, Fredeswinda
  • Sánchez Pernaute, Olga
  • Nuño Nuño, Laura
  • Bonilla, Gema
  • Balsa, Alejandro
  • Hernández González, Fernanda
  • Grafia, Ignacio
  • Prieto González, Sergio
  • Narvaez, Javier
  • Trallero Araguas, Ernesto
  • Selva O’Callaghan, Albert
  • Gualillo, Oreste
  • Castañeda, Santos
  • Cavagna, Lorenzo
  • Cifrian, José M.
  • González Gay, Miguel A.
MUC5B rs35705950 (G/T) is strongly associated with idiopathic pulmonary fibrosis (IPF) and also contributes to the risk of interstitial lung disease (ILD) in rheumatoid arthritis (RA-ILD) and chronic hypersensitivity pneumonitis (CHP). Due to this, we evaluated the implication of MUC5B rs35705950 in antisynthetase syndrome (ASSD), a pathology characterised by a high ILD incidence. 160 patients with ASSD (142 with ILD associated with ASSD [ASSD-ILD+]), 232 with ILD unrelated to ASSD (comprising 161 IPF, 27 RA-ILD and 44 CHP) and 534 healthy controls were genotyped. MUC5B rs35705950 frequency did not significantly differ between ASSD-ILD+ patients and healthy controls nor when ASSD patients were stratified according to the presence/absence of anti Jo-1 antibodies or ILD. No significant differences in MUC5B rs35705950 were also observed in ASSD-ILD+ patients with a usual interstitial pneumonia (UIP) pattern when compared to those with a non-UIP pattern. However, a statistically significant decrease of MUC5B rs35705950 GT, TT and T frequencies in ASSD-ILD+ patients compared to patients with ILD unrelated to ASSD was observed. In summary, our study does not support a role of MUC5B rs35705950 in ASSD. It also indicates that there are genetic differences between ILD associated with and that unrelated to ASSD., We are indebted to the patients and healthy controls for their essential collaboration to this study. We also thank the National DNA Bank Repository (Salamanca) for supplying part of the control samples. This study was partially supported by grants from the Foundation for Research in Rheumatology (FOREUM). RL-M is a recipient of a Miguel Servet type I programme fellowship from the 'Instituto de Salud Carlos III' (ISCIII), cofunded by the European Social Fund (ESF, `Investing in your future') (grant CP16/00033). SR-M is supported by funds of the RETICS Program (RD16/0012/0009), co-funded by the European Regional Development Fund (ERDF). VP-C is supported by a pre-doctoral grant from IDIVAL (PREVAL 18/01). VM is supported by funds of a Miguel Servet type I programme (grant CP16/00033) (ISCIII, co-funded by ESF). LL-G is supported by funds of PI18/00042 (ISCIII, co-funded by ERDF). OG is Staff Personnel of Xunta de Galicia (Servizo Galego de Saude, SERGAS) through a research-staff stabilization contract (ISCIII/SERGAS). OG,is member of RETICS Programme, RD16/0012/0014 (RIER: Red de Investigacion en Inflamacion y Enfermedades Reumaticas) via Instituto de Salud Carlos III (ISCIII) and FEDER. The work of OG (PI17/00409), was funded by Instituto de Salud Carlos III and FEDER. OG is a beneficiary of a project funded by Research Executive Agency of the European Union in the framework of MSCA-RISE Action of the H2020 Programme (Project number 734899). OG is beneficiary of a grant funded by Xunta de Galicia, Conselleri ' a de Educacio ' n, Universidade e Formacio ' n Profesional and Conselleri ' a de Economi ' a, Emprego e Industria (GAIN), GPC IN607B2019/10.
Addi. Archivo Digital para la Docencia y la Investigación
Publication Artículo científico (JournalArticle)

Influence of MUC5B gene on antisynthetase syndrome

  • López Mejías, Raquel
  • Remuzgo Martínez, Sara
  • Genre, Fernanda
  • Pulito Cueto, Verónica
  • Fernández Rozas, Sonia M.
  • Llorca, Javier
  • Iturbe Fernández, David
  • Mora Cuesta, Víctor M.
  • Ortego Centeno, Norberto
  • Pérez Gómez, Nair
  • Mera Varela, Antonio
  • Martínez Barrio, Julia
  • López Longo, Francisco Javier
  • Mijares, Verónica
  • Lera Gómez, Leticia
  • Usetti, María Piedad
  • Laporta, Rosalía
  • Pérez, Virginia
  • De Pablo Gafas, Alicia
  • Alfranca González, María Aránzazu
  • Calvo Alén, Jaime
  • Romero Bueno, Fredeswinda
  • Sanchez Pernaute, Olga
  • Nuno, Laura
  • Bonilla, Gema
  • Balsa, Alejandro
  • Hernández González, Fernanda
  • Grafia, Ignacio
  • Prieto González, Sergio
  • Narváez, Javier
  • Trallero Araguas, Ernesto
  • Selva O’Callaghan, Albert
  • Gualillo, Oreste
  • Castañeda, Santos
  • Cavagna, Lorenzo
  • Cifrian, José M.
  • González Gay, Miguel A.
MUC5B rs35705950 (G/T) is strongly associated with idiopathic pulmonary fibrosis (IPF) and also contributes to the risk of interstitial lung disease (ILD) in rheumatoid arthritis (RA-ILD) and chronic hypersensitivity pneumonitis (CHP). Due to this, we evaluated the implication of MUC5B rs35705950 in antisynthetase syndrome (ASSD), a pathology characterised by a high ILD incidence. 160 patients with ASSD (142 with ILD associated with ASSD [ASSD-ILD+]), 232 with ILD unrelated to ASSD (comprising 161 IPF, 27 RA-ILD and 44 CHP) and 534 healthy controls were genotyped. MUC5B rs35705950 frequency did not significantly differ between ASSD-ILD+ patients and healthy controls nor when ASSD patients were stratified according to the presence/absence of anti Jo-1 antibodies or ILD. No significant differences in MUC5B rs35705950 were also observed in ASSD-ILD+ patients with a usual interstitial pneumonia (UIP) pattern when compared to those with a non-UIP pattern. However, a statistically significant decrease of MUC5B rs35705950 GT, TT and T frequencies in ASSD-ILD+ patients compared to patients with ILD unrelated to ASSD was observed. In summary, our study does not support a role of MUC5B rs35705950 in ASSD. It also indicates that there are genetic differences between ILD associated with and that unrelated to ASSD., We are indebted to the patients and healthy controls for their essential collaboration to this study. We also thank the National DNA Bank Repository (Salamanca) for supplying part of the control samples. This study was partially supported by grants from the Foundation for Research in Rheumatology (FOREUM). RL-M is a recipient of a Miguel Servet type I programme fellowship from the ‘Instituto de Salud Carlos III’ (ISCIII), co-funded by the European Social Fund (ESF, ‘Investing in your future’) (grant CP16/00033). SR-M is supported by funds of the RETICS Program (RD16/0012/0009), co-funded by the European Regional Development Fund (ERDF). VP-C is supported by a pre-doctoral grant from IDIVAL (PREVAL 18/01). VM is supported by funds of a Miguel Servet type I programme (grant CP16/00033) (ISCIII, co-funded by ESF). LL-G is supported by funds of PI18/00042 (ISCIII, co-funded by ERDF). OG is Staff Personnel of Xunta de Galicia (Servizo Galego de Saude, SERGAS) through a research-staff stabilization contract (ISCIII/SERGAS). OG,is member of RETICS Programme, RD16/0012/0014 (RIER: Red de Investigación en Inflamación y Enfermedades Reumáticas) via Instituto de Salud Carlos III (ISCIII) and FEDER. The work of OG (PI17/00409), was funded by Instituto de Salud Carlos III and FEDER. OG is a beneficiary of a project funded by Research Executive Agency of the European Union in the framework of MSCA-RISE Action of the H2020 Programme (Project number 734899). OG is beneficiary of a grant funded by Xunta de Galicia, Consellería de Educación, Universidade e Formación Profesional and Consellería de Economía, Emprego e Industria (GAIN), GPC IN607B2019/10.
RUC. Repositorio da Universidade da Coruña
Publication Artículo científico (JournalArticle)

The Treatment With the SGLT2 Inhibitor Empagliflozin Modifies the Hepatic Metabolome of Male Zucker Diabetic Fatty Rats Towards a Protective Profile

  • Aragón Herrera, Alana
  • Otero-Santiago, Manuel
  • Anido Varela, Laura
  • Moraña Fernández, Sandra
  • Campos-Toimil, Manuel
  • García-Caballero, Tomás
  • Barral, Luis
  • Tarazón, Estefanía
  • Roselló-Lletí, Esther
  • Portolés, Manuel
  • Gualillo, Oreste
  • Moscoso, Isabel
  • Lage Fernández, Ricardo
  • González-Juanatey, José Ramón
  • Feijóo-Bandín, Sandra
  • Lago, Francisca
[Abstract] The EMPA-REG OUTCOME (Empagliflozin, Cardiovascular Outcome Event Trial in patients with Type 2 Diabetes Mellitus (T2DM)) trial evidenced the potential of sodium-glucose cotransporter 2 (SGLT2) inhibitors for the treatment of patients with diabetes and cardiovascular disease. Recent evidences have shown the benefits of the SGLT2 inhibitor empagliflozin on improving liver steatosis and fibrosis in patients with T2DM. Metabolomic studies have been shown to be very useful to improve the understanding of liver pathophysiology during the development and progression of metabolic hepatic diseases, and because the effects of empagliflozin and of other SGLT2 inhibitors on the complete metabolic profile of the liver has never been analysed before, we decided to study the impact on the liver of male Zucker diabetic fatty (ZDF) rats of a treatment for 6 weeks with empagliflozin using an untargeted metabolomics approach, with the purpose to help to clarify the benefits of the use of empagliflozin at hepatic level. We found that empagliflozin is able to change the hepatic lipidome towards a protective profile, through an increase of monounsaturated and polyunsaturated glycerides, phosphatidylcholines, phosphatidylethanolamines, lysophosphatidylinositols and lysophosphatidylcholines. Empagliflozin also induces a decrease in the levels of the markers of inflammation IL-6, chemerin and chemerin receptor in the liver. Our results provide new evidences regarding the molecular pathways through which empagliflozin could exert hepatoprotector beneficial effects in T2DM., This work was supported by Boehringer Ingelheim Pharma GmbH and Co., by the National Institute of Health “Fondo de Investigaciones Sanitarias del Instituto de Salud Carlos III” Madrid, Spain (PI15/00681, PI17/00409, PI18/00821, PI20/00902, RETICS Programme RD16/0012/0014 and CIBER de Enfermedades Cardiovasculares (CIBERCV)); European Regional Development Fund (FEDER) and European Union framework MSCA-RISE-H2020 Programme (Project number 734899). AH-A was funded by predoctoral research grants from Xunta de Galicia and FPU Program of the Spanish Ministry of Science, Innovation and Universities (Spain); MF-S was funded by the predoctoral research grants “Programa Científico do Centro de Investigación en Medicina Molecular e Enfermidades Crónicas (CiMUS) (Spain) and Xunta de Galicia; and AV-L was funded by the predoctoral research grant from the PFIS Program of the Spanish Ministry of Science and Instituto de Salud Carlos III (Spain)
Dipòsit Digital de la UB
Publication Artículo científico (JournalArticle)

BAFF, APRIL and BAFFR on the pathogenesis of Immunoglobulin-A vasculitis

  • Prieto Peña, Diana
  • Genre, Fernanda
  • Remuzgo Martínez, Sara
  • Pulito Cueto, Verónica
  • Atienza Mateo, Belén
  • Llorca, Javier
  • Sevilla Pérez, Belén
  • Ortego Centeno, Norberto
  • Lera Gómez, Leticia
  • Leonardo, María Teresa
  • Peñalba, Ana
  • Narváez García, Francisco Javier
  • Martín Penagos, Luis
  • Rodrigo, Emilio
  • Miranda Filloy, José A.
  • Caminal Montero, Luis
  • Collado, Paz
  • Sánchez Pérez, Javier
  • Argila, Diego de
  • Rubio, Esteban
  • Luque, Manuel León
  • Blanco Madrigal, Juan María
  • Galíndez Agirregoikoa, Eva
  • Gualillo, Oreste
  • Martín, Javier
  • Castañeda, Santos
  • Blanco, Ricardo
  • González Gay, Miguel A.
  • López Mejías, Raquel
BAFF, APRIL and BAFF-R are key proteins involved in the development of B-lymphocytes and autoimmunity. Additionally, BAFF, APRIL and BAFFR polymorphisms were associated with immune-mediated conditions, being BAFF GCTGT>A a shared insertion-deletion genetic variant for several autoimmune diseases. Accordingly, we assessed whether BAFF, APRIL and BAFFR represent novel genetic risk factors for Immunoglobulin-A vasculitis (IgAV), a predominantly B-lymphocyte inflammatory condition. BAFF rs374039502, which colocalizes with BAFF GCTGT>A, and two tag variants within APRIL (rs11552708 and rs6608) and BAFFR (rs7290134 and rs77874543) were genotyped in 386 Caucasian IgAV patients and 806 matched healthy controls. No genotypes or alleles differences were observed between IgAV patients and controls when BAFF, APRIL and BAFFR variants were analysed independently. Likewise, no statistically significant differences were found in the genotype and allele frequencies of BAFF, APRIL or BAFFR when IgAV patients were stratified according to the age at disease onset or to the presence/absence of gastrointestinal (GI) or renal manifestations. Similar results were disclosed when APRIL and BAFFR haplotypes were compared between IgAV patients and controls and between IgAV patients stratified according to the clinical characteristics mentioned above. Our results suggest that BAFF, APRIL and BAFFR do not contribute to the genetic network underlying IgAV.
Dipòsit Digital de la UB
Publication Artículo científico (JournalArticle)

IgA Vasculitis: Influence of CD40, BLK and BANK1 Gene Polymorphisms

  • Liz, Joao Carlos Batista
  • Genre, Fernanda
  • Pulito Cueto, Verónica
  • Remuzgo Martínez, Sara
  • Prieto Peña, Diana
  • Márquez, Ana
  • Ortego Centeno, Norberto
  • Leonardo, María Teresa
  • Peñalba, Ana
  • Narváez García, Francisco Javier
  • Martín Penagos, Luis
  • Belmar Vega, Lara
  • Gómez Fernández, Cristina
  • Miranda Filloy, José A.
  • Caminal Montero, Luis
  • Collado, Paz
  • De Árgila, Diego
  • Quiroga Colina, Patricia
  • Vicente Rabaneda, Esther F.
  • Triguero Martínez, Ana
  • Rubio, Esteban
  • León Luque, Manuel
  • Blanco Madrigal, Juan María
  • Galíndez Agirregoikoa, Eva
  • Martín, Javier
  • Gualillo, Oreste
  • Blanco, Ricardo
  • Castañeda, Santos
  • González Gay, Miguel A.
  • López Mejías, Raquel
CD40, BLK and BANK1 genes involved in the development and signaling of B-cells are identified as susceptibility loci for numerous inflammatory diseases. Accordingly, we assessed the potential influence of CD40, BLK and BANK1 on the pathogenesis of immunoglobulin-A vasculitis (IgAV), predominantly a B-lymphocyte inflammatory condition. Three genetic variants within CD40 (rs1883832, rs1535045, rs4813003) and BLK (rs2254546, rs2736340, rs2618476) as well as two BANK1 polymorphisms (rs10516487, rs3733197), previously associated with inflammatory diseases, were genotyped in 382 Caucasian patients with IgAV and 955 sex- and ethnically matched healthy controls. No statistically significant differences were observed in the genotype and allele frequencies of CD40, BLK and BANK1 when IgAV patients and healthy controls were compared. Similar results were found when CD40, BLK and BANK1 genotypes or alleles frequencies were compared between patients with IgAV stratified according to the age at disease onset or to the presence/absence of gastrointestinal or renal manifestations. Moreover, no CD40, BLK and BANK1 haplotype differences were disclosed between patients with IgAV and healthy controls and between patients with IgAV stratified according to the clinical characteristics mentioned above. Our findings indicate that CD40, BLK and BANK1 do not contribute to the genetic background of IgAV.
Dipòsit Digital de la UB
Publication Artículo científico (JournalArticle)

Role of the IL33 and IL1RL1 pathway in the pathogenesis of Immunoglobulin A vasculitis

  • Prieto Peña, Diana
  • Remuzgo Martínez, Sara
  • Genre, Fernanda
  • Pulito Cueto, Verónica
  • Atienza Mateo, Belén
  • Llorca Ballester, Jaime
  • Sevilla Pérez, Belén
  • Ortego Centeno, Norberto
  • Marquez, Ana
  • Lera Gómez, Leticia
  • Leonardo, María Teresa
  • Peñalba, Ana
  • Narváez García, Francisco Javier
  • Martín Penagos, Luis
  • Rodrigo, Emilio
  • Miranda Filloy, José A.
  • Caminal Montero, Luis
  • Collado, Paz
  • Sánchez Pérez, Javier
  • Argila, Diego de
  • Rubio, Esteban
  • León Luque, Manuel
  • Blanco Madrigal, Juan María
  • Galíndez Agirregoikoa, Eva
  • Gualillo, Oreste
  • Martín, Javier
  • Castañeda, Santos
  • Blanco, Ricardo
  • González Gay, Miguel A.
  • López Mejías, Raquel
Cytokines signalling pathway genes are crucial factors of the genetic network underlying the pathogenesis of Immunoglobulin-A vasculitis (IgAV), an inflammatory vascular condition. An influence of the interleukin (IL)33- IL1 receptor like (IL1RL)1 signalling pathway on the increased risk of several immune-mediated diseases has been described. Accordingly, we assessed whether the IL33-IL1RL1 pathway represents a novel genetic risk factor for IgAV. Three tag polymorphisms within IL33 (rs3939286, rs7025417 and rs7044343) and three within IL1RL1 (rs2310173, rs13015714 and rs2058660), that also were previously associated with several inflammatory diseases, were genotyped in 380 Caucasian IgAV patients and 845 matched healthy controls. No genotypes or alleles differences were observed between IgAV patients and controls when IL33 and IL1RL1 variants were analysed independently. Likewise, no statistically significant differences were found in IL33 or IL1RL1 genotype and allele frequencies when IgAV patients were stratified according to the age at disease onset or to the presence/absence of gastrointestinal (GI) or renal manifestations. Similar results were disclosed when IL33 and IL1RL1 haplotypes were compared between IgAV patients and controls and between IgAV patients stratified according to the clinical characteristics mentioned above. Our results suggest that the IL33-IL1RL1 signalling pathway does not contribute to the genetic network underlying IgAV.
Dipòsit Digital de la UB
Publication Artículo científico (JournalArticle)

Role of MUC1 rs4072037 polymorphism and serum KL-6 levels in patients with antisynthetase syndrome

  • Remuzgo Martínez, Sara
  • Atienza Mateo, Belén
  • Ocejo Vinyals, J. Gonzalo
  • Genre, Fernanda
  • Pulito Cueto, Verónica
  • Mora Cuesta, Víctor M.
  • Iturbe Fernández, David
  • Lera Gómez, Leticia
  • Pérez Fernández, Raquel
  • Prieto Peña, Diana
  • Irure, Juan
  • Romero Bueno, Fredeswinda
  • Sanchez Pernaute, Olga
  • Alonso Moralejo, Rodrigo
  • Nuño-Nuño, Laura
  • Bonilla, Gema
  • Vicente Rabaneda, Esther F.
  • Grafia, Ignacio
  • Prieto González, Sergio
  • Narváez García, Francisco Javier
  • Trallero Araguas, Ernesto
  • Selva O&apos;Callaghan, Albert
  • Ortego Centeno, Norberto
  • Pérez Gómez, Nair
  • Mera, Antonio
  • Martínez Barrio, Julia
  • Moriano, Clara
  • Díez, Elvira
  • Calvo Alén, Jaime
  • Balsa, Alejandro
  • Ussetti, María Piedad
  • Laporta, Rosalía
  • Berastegui, Cristina
  • Solé, Amparo
  • Gualillo, Oreste
  • Cavagna, Lorenzo
  • Cifrián, José M.
  • Renzoni, Elisabetta A.
  • Castañeda, Santos
  • López Mejías, Raquel
  • González Gay, Miguel A.
  • Spanish Biomarkers Of Antisynthetase Syndrome Consortium
  • Spanish Biomarkers Of Interstitial Lung Disease Consortium
Mucin 1/Krebs von den Lungen-6 (KL-6) is proposed as a serum biomarker of several interstitial lung diseases (ILDs), including connective tissue disorders associated with ILD. However, it has not been studied in a large cohort of Caucasian antisynthetase syndrome (ASSD) patients. Consequently, we assessed the role of MUC1 rs4072037 and serum KL-6 levels as a potential biomarker of ASSD susceptibility and for the differential diagnosis between patients with ILD associated with ASSD (ASSD-ILD +) and idiopathic pulmonary fibrosis (IPF). 168 ASSD patients (149 ASSD-ILD +), 174 IPF patients and 523 healthy controls were genotyped for MUC1 rs4072037 T > C. Serum KL-6 levels were determined in a subgroup of individuals. A significant increase of MUC1 rs4072037 CC genotype and C allele frequencies was observed in ASSD patients compared to healthy controls. Likewise, MUC1 rs4072037 TC and CC genotypes and C allele frequencies were significantly different between ASSD-ILD+ and IPF patients. Additionally, serum KL-6 levels were significantly higher in ASSD patients compared to healthy controls. Nevertheless, no differences in serum KL-6 levels were found between ASSD-ILD+ and IPF patients. Our results suggest that the presence of MUC1 rs4072037 C allele increases the risk of ASSD and it could be a useful genetic biomarker for the differential diagnosis between ASSD-ILD+ and IPF patients.
Dipòsit Digital de la UB
Publication Artículo científico (JournalArticle)

Influence of MUC5B gene on antisynthetase syndrome

  • López Mejías, Raquel
  • Remuzgo Martínez, Sara
  • Genre, Fernanda
  • Pulito Cueto, Verónica
  • Fernández Rozas, Sonia M.
  • Llorca, Javier
  • Iturbe Fernandez, David
  • Mora Cuesta, Víctor M.
  • Ortego Centeno, Norberto
  • Pérez Gómez, Norberto
  • Mera Varela, Antonio
  • Martínez Barrio, Julia
  • López Longo, Francisco J.
  • Mijares, Verónica
  • Lera Gómez, Leticia
  • Ussetti, María Piedad
  • Laporta, Rosalía
  • Pérez, Virginia
  • Pablo Gafas, Alicia de
  • Alfranca González, María Aránzazu
  • Calvo Alén, Jaime
  • Romero Bueno, Fredeswinda
  • Sánchez Pernaute, Olga
  • Nuno, Laura
  • Bonilla, Gema
  • Balsa, Alejandro
  • Hernández González, Fernanda
  • Grafia, Ignacio
  • Prieto González, Sergio
  • Narváez García, Francisco Javier
  • Trallero Araguas, Ernesto
  • Selva O&apos;Callaghan, Albert
  • Gualillo, Oreste
  • Castañeda, Santos
  • Cavagna, Lorenzo
  • Cifrian, José M.
  • González Gay, Miguel A.
MUC5B rs35705950 (G/T) is strongly associated with idiopathic pulmonary fibrosis (IPF) and also contributes to the risk of interstitial lung disease (ILD) in rheumatoid arthritis (RA-ILD) and chronic hypersensitivity pneumonitis (CHP). Due to this, we evaluated the implication of MUC5B rs35705950 in antisynthetase syndrome (ASSD), a pathology characterised by a high ILD incidence. 160 patients with ASSD (142 with ILD associated with ASSD [ASSD-ILD+]), 232 with ILD unrelated to ASSD (comprising 161 IPF, 27 RA-ILD and 44 CHP) and 534 healthy controls were genotyped. MUC5B rs35705950 frequency did not significantly differ between ASSD-ILD+ patients and healthy controls nor when ASSD patients were stratified according to the presence/absence of anti Jo-1 antibodies or ILD. No significant differences in MUC5B rs35705950 were also observed in ASSD-ILD+ patients with a usual interstitial pneumonia (UIP) pattern when compared to those with a non-UIP pattern. However, a statistically significant decrease of MUC5B rs35705950 GT, TT and T frequencies in ASSD-ILD+ patients compared to patients with ILD unrelated to ASSD was observed. In summary, our study does not support a role of MUC5B rs35705950 in ASSD. It also indicates that there are genetic differences between ILD associated with and that unrelated to ASSD.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

BAFF, APRIL and BAFFR on the pathogenesis of Immunoglobulin-A vasculitis

  • Prieto-Peña, Diana
  • Genre, Fernanda
  • Remuzgo-Martínez, Sara
  • Pulito-Cueto, Verónica
  • Atienza-Mateo, Belén
  • Llorca, Javier
  • Sevilla-Pérez, Belén
  • Ortego-Centeno, Norberto
  • Lera-Gómez, Leticia
  • Leonardo, María Teresa
  • Peñalba, Ana
  • Narváez, Javier
  • Martín-Penagos, Luis
  • Rodrigo, E.
  • Miranda-Filloy, J. A.
  • Caminal-Montero, Luis
  • Collado, Paz
  • Sánchez Pérez, J.
  • Árgila, Diego de
  • Rubio, E.
  • León Luque, Manuel
  • Blanco-Madrigal, Juan María
  • Galíndez-Agirregoikoa, Eva
  • Gualillo, Oreste
  • Martín, J.
  • Castañeda, Santos
  • Blanco, Ricardo
  • González-Gay, Miguel A.
  • López-Mejías, Raquel
BAFF, APRIL and BAFF-R are key proteins involved in the development of B-lymphocytes and autoimmunity. Additionally, BAFF, APRIL and BAFFR polymorphisms were associated with immune-mediated conditions, being BAFF GCTGT>A a shared insertion-deletion genetic variant for several autoimmune diseases. Accordingly, we assessed whether BAFF, APRIL and BAFFR represent novel genetic risk factors for Immunoglobulin-A vasculitis (IgAV), a predominantly B-lymphocyte inflammatory condition. BAFF rs374039502, which colocalizes with BAFF GCTGT>A, and two tag variants within APRIL (rs11552708 and rs6608) and BAFFR (rs7290134 and rs77874543) were genotyped in 386 Caucasian IgAV patients and 806 matched healthy controls. No genotypes or alleles differences were observed between IgAV patients and controls when BAFF, APRIL and BAFFR variants were analysed independently. Likewise, no statistically significant differences were found in the genotype and allele frequencies of BAFF, APRIL or BAFFR when IgAV patients were stratified according to the age at disease onset or to the presence/absence of gastrointestinal (GI) or renal manifestations. Similar results were disclosed when APRIL and BAFFR haplotypes were compared between IgAV patients and controls and between IgAV patients stratified according to the clinical characteristics mentioned above. Our results suggest that BAFF, APRIL and BAFFR do not contribute to the genetic network underlying IgAV., We are indebted to the patients and healthy controls for their essential collaboration to this study. We also thank the National DNA Bank Repository (Salamanca) for supplying part of the control samples.This study was supported by European Union FEDER funds and `Fondo de Investigaciones Sanitarias ́ (grant PI18/00042) from ‘Instituto de Salud Carlos III’ (ISCIII, Health Ministry, Spain). DP-P is a recipient of a Río Hortega programme fellowship from the ISCIII, co-funded by the European Social Fund (ESF, `Investing in your future ́) (grant number CM20/00006). SR-M is supported by funds of the RETICS Program (RD16/0012/0009) (ISCIII, co-funded by the European Regional Development Fund (ERDF)). VP-C is supported by a pre-doctoral grant from IDIVAL (PREVAL 18/01). BA-M is a recipient of a `López Albo ́ Post-Residency Programme funded by Servicio Cántabro de Salud. LL-G is supported by funds from IDIVAL (INNVAL20/06). OG is staff person-nel of Xunta de Galicia (Servizo Galego de Saude (SERGAS)) through a research-staff stabilization contract (ISCIII/SERGAS) and his work is funded by ISCIII and the European Union FEDER fund (grant numbers RD16/0012/0014 (RIER) and PI17/00409). He is beneficiary of project funds from the Research Executive Agency (REA) of the European Union in the framework of MSCA-RISE Action of the H2020 Programme, project 734899—Olive-Net. RL-M is a recipient of a Miguel Servet type I programme fellowship from the ISCIII, co-funded by ESF (`Investing in your future ́) (grant number CP16/00033)
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

IgA Vasculitis: Influence of CD40, BLK and BANK1 Gene Polymorphisms

  • Batista-Liz, Joao Carlos
  • Genre, Fernanda
  • Pulito-Cueto, Verónica
  • Remuzgo-Martínez, Sara
  • Prieto-Peña, Diana
  • Márquez, Ana
  • Ortego-Centeno, Norberto
  • Leonardo, María Teresa
  • Peñalba, Ana
  • Narváez, Javier
  • Martín-Penagos, Luis
  • Belmar-Vega, Lara
  • Gómez Fernández, Cristina
  • Miranda-Filloy, J. A.
  • Caminal-Montero, Luis
  • Collado, Paz
  • Árgila, Diego de
  • Quiroga, Patricia
  • Vicente, Esther
  • Triguero-Martínez, Ana
  • Rubio, Esteban
  • León Luque, Manuel
  • Blanco-Madrigal, Juan María
  • Galíndez-Agirregoikoa, E.
  • Martín, Javier
  • Gualillo, Oreste
  • Blanco, Ricardo
  • Castañeda, Santos
  • González-Gay, Miguel A.
  • López-Mejías, Raquel
CD40, BLK and BANK1 genes involved in the development and signaling of B-cells are identified as susceptibility loci for numerous inflammatory diseases. Accordingly, we assessed the potential influence of CD40, BLK and BANK1 on the pathogenesis of immunoglobulin-A vasculitis (IgAV), predominantly a B-lymphocyte inflammatory condition. Three genetic variants within CD40 (rs1883832, rs1535045, rs4813003) and BLK (rs2254546, rs2736340, rs2618476) as well as two BANK1 polymorphisms (rs10516487, rs3733197), previously associated with inflammatory diseases, were genotyped in 382 Caucasian patients with IgAV and 955 sex- and ethnically matched healthy controls. No statistically significant differences were observed in the genotype and allele frequencies of CD40, BLK and BANK1 when IgAV patients and healthy controls were compared. Similar results were found when CD40, BLK and BANK1 genotypes or alleles frequencies were compared between patients with IgAV stratified according to the age at disease onset or to the presence/absence of gastrointestinal or renal manifestations. Moreover, no CD40, BLK and BANK1 haplotype differences were disclosed between patients with IgAV and healthy controls and between patients with IgAV stratified according to the clinical characteristics mentioned above. Our findings indicate that CD40, BLK and BANK1 do not contribute to the genetic background of IgAV., This study was supported by European Union FEDER funds and “Fondo de Investigaciones Sanitarias” (grants PI18/00042 and PI21/00042) from “Instituto de Salud Carlos III” (ISCIII, Health Ministry, Spain). D.P.-P. is a recipient of a Río Hortega program fellowship from the ISCIII, co-funded by the European Social Fund (ESF, “Investing in your future”) (grant number CM20/00006). F.G. is supported by funds of the RICORS Program from ISCIII, co-funded by the European Union (grant number RD21/0002/0025). V.P.-C. is supported by funds of PI18/00042. S.R.-M. is supported by funds of the RETICS Program (RD16/0012/0009) (ISCIII, co-funded by the European Regional Development Fund (ERDF)). O.G. is a staff member of Xunta de Galicia (Servizo Galego de Saude (SERGAS)) through a research-staff stabilization contract (ISCIII/SERGAS) and his work is funded by ISCIII and the European Union FEDER fund (grant numbers RD16/0012/0014 (RIER) and PI17/00409). He is a beneficiary of project funds from the Research Executive Agency (REA) of the European Union in the framework of MSCA-RISE Action of the H2020 Program, project 734899—Olive-Net. R.L.-M. is a recipient of a Miguel Servet type II program fellowship from the ISCIII, co-funded by ESF (“Investing in your future”) (grant number CPII21/00004)., Peer reviewed
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

IgA Vasculitis: Influence of CD40, BLK and BANK1 Gene Polymorphisms

  • Liz, Joao Carlos Batista
  • Genre, Fernanda
  • Pulito Cueto, Verónica
  • Remuzgo Martínez, Sara
  • Prieto Peña, Diana
  • Márquez, Ana
  • Ortego Centeno, Norberto
  • Leonardo, María Teresa
  • Peñalba, Ana
  • Narváez García, Francisco Javier
  • Martín Penagos, Luis
  • Belmar Vega, Lara
  • Gómez Fernández, Cristina
  • Miranda Filloy, José A.
  • Caminal Montero, Luis
  • Collado, Paz
  • De Árgila, Diego
  • Quiroga Colina, Patricia
  • Vicente Rabaneda, Esther F.
  • Triguero Martínez, Ana
  • Rubio, Esteban
  • León Luque, Manuel
  • Blanco Madrigal, Juan María
  • Galíndez Agirregoikoa, Eva
  • Martín, Javier
  • Gualillo, Oreste
  • Blanco, Ricardo
  • Castañeda, Santos
  • González Gay, Miguel A.
  • López Mejías, Raquel
CD40, BLK and BANK1 genes involved in the development and signaling of B-cells are identified as susceptibility loci for numerous inflammatory diseases. Accordingly, we assessed the potential influence of CD40, BLK and BANK1 on the pathogenesis of immunoglobulin-A vasculitis (IgAV), predominantly a B-lymphocyte inflammatory condition. Three genetic variants within CD40 (rs1883832, rs1535045, rs4813003) and BLK (rs2254546, rs2736340, rs2618476) as well as two BANK1 polymorphisms (rs10516487, rs3733197), previously associated with inflammatory diseases, were genotyped in 382 Caucasian patients with IgAV and 955 sex- and ethnically matched healthy controls. No statistically significant differences were observed in the genotype and allele frequencies of CD40, BLK and BANK1 when IgAV patients and healthy controls were compared. Similar results were found when CD40, BLK and BANK1 genotypes or alleles frequencies were compared between patients with IgAV stratified according to the age at disease onset or to the presence/absence of gastrointestinal or renal manifestations. Moreover, no CD40, BLK and BANK1 haplotype differences were disclosed between patients with IgAV and healthy controls and between patients with IgAV stratified according to the clinical characteristics mentioned above. Our findings indicate that CD40, BLK and BANK1 do not contribute to the genetic background of IgAV.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Influence of MUC5B gene on antisynthetase syndrome

  • López Mejías, Raquel
  • Remuzgo Martínez, Sara
  • Genre, Fernanda
  • Pulito Cueto, Verónica
  • Fernández Rozas, Sonia M.
  • Llorca, Javier
  • Iturbe Fernandez, David
  • Mora Cuesta, Víctor M.
  • Ortego Centeno, Norberto
  • Pérez Gómez, Norberto
  • Mera Varela, Antonio
  • Martínez Barrio, Julia
  • López Longo, Francisco J.
  • Mijares, Verónica
  • Lera Gómez, Leticia
  • Ussetti, María Piedad
  • Laporta, Rosalía
  • Pérez, Virginia
  • Pablo Gafas, Alicia de
  • Alfranca González, María Aránzazu
  • Calvo Alén, Jaime
  • Romero Bueno, Fredeswinda
  • Sánchez Pernaute, Olga
  • Nuno, Laura
  • Bonilla, Gema
  • Balsa, Alejandro
  • Hernández González, Fernanda
  • Grafia, Ignacio
  • Prieto González, Sergio
  • Narváez García, Francisco Javier
  • Trallero Araguas, Ernesto
  • Selva O'Callaghan, Albert
  • Gualillo, Oreste
  • Castañeda, Santos
  • Cavagna, Lorenzo
  • Cifrian, José M.
  • González Gay, Miguel A.
MUC5B rs35705950 (G/T) is strongly associated with idiopathic pulmonary fibrosis (IPF) and also contributes to the risk of interstitial lung disease (ILD) in rheumatoid arthritis (RA-ILD) and chronic hypersensitivity pneumonitis (CHP). Due to this, we evaluated the implication of MUC5B rs35705950 in antisynthetase syndrome (ASSD), a pathology characterised by a high ILD incidence. 160 patients with ASSD (142 with ILD associated with ASSD [ASSD-ILD+]), 232 with ILD unrelated to ASSD (comprising 161 IPF, 27 RA-ILD and 44 CHP) and 534 healthy controls were genotyped. MUC5B rs35705950 frequency did not significantly differ between ASSD-ILD+ patients and healthy controls nor when ASSD patients were stratified according to the presence/absence of anti Jo-1 antibodies or ILD. No significant differences in MUC5B rs35705950 were also observed in ASSD-ILD+ patients with a usual interstitial pneumonia (UIP) pattern when compared to those with a non-UIP pattern. However, a statistically significant decrease of MUC5B rs35705950 GT, TT and T frequencies in ASSD-ILD+ patients compared to patients with ILD unrelated to ASSD was observed. In summary, our study does not support a role of MUC5B rs35705950 in ASSD. It also indicates that there are genetic differences between ILD associated with and that unrelated to ASSD.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Role of MUC1 rs4072037 polymorphism and serum KL-6 levels in patients with antisynthetase syndrome

  • Remuzgo Martínez, Sara
  • Atienza Mateo, Belén
  • Ocejo Vinyals, J. Gonzalo
  • Genre, Fernanda
  • Pulito Cueto, Verónica
  • Mora Cuesta, Víctor M.
  • Iturbe Fernández, David
  • Lera Gómez, Leticia
  • Pérez Fernández, Raquel
  • Prieto Peña, Diana
  • Irure, Juan
  • Romero Bueno, Fredeswinda
  • Sanchez Pernaute, Olga
  • Alonso Moralejo, Rodrigo
  • Nuño-Nuño, Laura
  • Bonilla, Gema
  • Vicente Rabaneda, Esther F.
  • Grafia, Ignacio
  • Prieto González, Sergio
  • Narváez García, Francisco Javier
  • Trallero Araguas, Ernesto
  • Selva O&apos;Callaghan, Albert
  • Ortego Centeno, Norberto
  • Pérez Gómez, Nair
  • Mera, Antonio
  • Martínez Barrio, Julia
  • Moriano, Clara
  • Díez, Elvira
  • Calvo Alén, Jaime
  • Balsa, Alejandro
  • Ussetti, María Piedad
  • Laporta, Rosalía
  • Berastegui, Cristina
  • Solé, Amparo
  • Gualillo, Oreste
  • Cavagna, Lorenzo
  • Cifrián, José M.
  • Renzoni, Elisabetta A.
  • Castañeda, Santos
  • López Mejías, Raquel
  • González Gay, Miguel A.
  • Spanish Biomarkers Of Antisynthetase Syndrome Consortium
  • Spanish Biomarkers Of Interstitial Lung Disease Consortium
Mucin 1/Krebs von den Lungen-6 (KL-6) is proposed as a serum biomarker of several interstitial lung diseases (ILDs), including connective tissue disorders associated with ILD. However, it has not been studied in a large cohort of Caucasian antisynthetase syndrome (ASSD) patients. Consequently, we assessed the role of MUC1 rs4072037 and serum KL-6 levels as a potential biomarker of ASSD susceptibility and for the differential diagnosis between patients with ILD associated with ASSD (ASSD-ILD +) and idiopathic pulmonary fibrosis (IPF). 168 ASSD patients (149 ASSD-ILD +), 174 IPF patients and 523 healthy controls were genotyped for MUC1 rs4072037 T > C. Serum KL-6 levels were determined in a subgroup of individuals. A significant increase of MUC1 rs4072037 CC genotype and C allele frequencies was observed in ASSD patients compared to healthy controls. Likewise, MUC1 rs4072037 TC and CC genotypes and C allele frequencies were significantly different between ASSD-ILD+ and IPF patients. Additionally, serum KL-6 levels were significantly higher in ASSD patients compared to healthy controls. Nevertheless, no differences in serum KL-6 levels were found between ASSD-ILD+ and IPF patients. Our results suggest that the presence of MUC1 rs4072037 C allele increases the risk of ASSD and it could be a useful genetic biomarker for the differential diagnosis between ASSD-ILD+ and IPF patients.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

BAFF, APRIL and BAFFR on the pathogenesis of Immunoglobulin-A vasculitis

  • Prieto Peña, Diana
  • Genre, Fernanda
  • Remuzgo Martínez, Sara
  • Pulito Cueto, Verónica
  • Atienza Mateo, Belén
  • Llorca, Javier
  • Sevilla Pérez, Belén
  • Ortego Centeno, Norberto
  • Lera Gómez, Leticia
  • Leonardo, María Teresa
  • Peñalba, Ana
  • Narváez García, Francisco Javier
  • Martín Penagos, Luis
  • Rodrigo, Emilio
  • Miranda Filloy, José A.
  • Caminal Montero, Luis
  • Collado, Paz
  • Sánchez Pérez, Javier
  • Argila, Diego de
  • Rubio, Esteban
  • Luque, Manuel León
  • Blanco Madrigal, Juan María
  • Galíndez Agirregoikoa, Eva
  • Gualillo, Oreste
  • Martín, Javier
  • Castañeda, Santos
  • Blanco, Ricardo
  • González Gay, Miguel A.
  • López Mejías, Raquel
BAFF, APRIL and BAFF-R are key proteins involved in the development of B-lymphocytes and autoimmunity. Additionally, BAFF, APRIL and BAFFR polymorphisms were associated with immune-mediated conditions, being BAFF GCTGT>A a shared insertion-deletion genetic variant for several autoimmune diseases. Accordingly, we assessed whether BAFF, APRIL and BAFFR represent novel genetic risk factors for Immunoglobulin-A vasculitis (IgAV), a predominantly B-lymphocyte inflammatory condition. BAFF rs374039502, which colocalizes with BAFF GCTGT>A, and two tag variants within APRIL (rs11552708 and rs6608) and BAFFR (rs7290134 and rs77874543) were genotyped in 386 Caucasian IgAV patients and 806 matched healthy controls. No genotypes or alleles differences were observed between IgAV patients and controls when BAFF, APRIL and BAFFR variants were analysed independently. Likewise, no statistically significant differences were found in the genotype and allele frequencies of BAFF, APRIL or BAFFR when IgAV patients were stratified according to the age at disease onset or to the presence/absence of gastrointestinal (GI) or renal manifestations. Similar results were disclosed when APRIL and BAFFR haplotypes were compared between IgAV patients and controls and between IgAV patients stratified according to the clinical characteristics mentioned above. Our results suggest that BAFF, APRIL and BAFFR do not contribute to the genetic network underlying IgAV.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Role of the IL33 and IL1RL1 pathway in the pathogenesis of Immunoglobulin A vasculitis

  • Prieto Peña, Diana
  • Remuzgo Martínez, Sara
  • Genre, Fernanda
  • Pulito Cueto, Verónica
  • Atienza Mateo, Belén
  • Llorca Ballester, Jaime
  • Sevilla Pérez, Belén
  • Ortego Centeno, Norberto
  • Marquez, Ana
  • Lera Gómez, Leticia
  • Leonardo, María Teresa
  • Peñalba, Ana
  • Narváez García, Francisco Javier
  • Martín Penagos, Luis
  • Rodrigo, Emilio
  • Miranda Filloy, José A.
  • Caminal Montero, Luis
  • Collado, Paz
  • Sánchez Pérez, Javier
  • Argila, Diego de
  • Rubio, Esteban
  • León Luque, Manuel
  • Blanco Madrigal, Juan María
  • Galíndez Agirregoikoa, Eva
  • Gualillo, Oreste
  • Martín, Javier
  • Castañeda, Santos
  • Blanco, Ricardo
  • González Gay, Miguel A.
  • López Mejías, Raquel
Cytokines signalling pathway genes are crucial factors of the genetic network underlying the pathogenesis of Immunoglobulin-A vasculitis (IgAV), an inflammatory vascular condition. An influence of the interleukin (IL)33- IL1 receptor like (IL1RL)1 signalling pathway on the increased risk of several immune-mediated diseases has been described. Accordingly, we assessed whether the IL33-IL1RL1 pathway represents a novel genetic risk factor for IgAV. Three tag polymorphisms within IL33 (rs3939286, rs7025417 and rs7044343) and three within IL1RL1 (rs2310173, rs13015714 and rs2058660), that also were previously associated with several inflammatory diseases, were genotyped in 380 Caucasian IgAV patients and 845 matched healthy controls. No genotypes or alleles differences were observed between IgAV patients and controls when IL33 and IL1RL1 variants were analysed independently. Likewise, no statistically significant differences were found in IL33 or IL1RL1 genotype and allele frequencies when IgAV patients were stratified according to the age at disease onset or to the presence/absence of gastrointestinal (GI) or renal manifestations. Similar results were disclosed when IL33 and IL1RL1 haplotypes were compared between IgAV patients and controls and between IgAV patients stratified according to the clinical characteristics mentioned above. Our results suggest that the IL33-IL1RL1 signalling pathway does not contribute to the genetic network underlying IgAV.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Influence of MUC5B gene on antisynthetase syndrome

  • López-Mejías, Raquel|||0000-0003-0548-2689
  • Remuzgo-Martínez, Sara|||0000-0003-4455-7241
  • Genre, Fernanda|||0000-0003-3612-1448
  • Pulito-Cueto, Verónica|||0000-0002-3534-8467
  • Fernández Rozas, Sonia María
  • Llorca, Javier|||0000-0001-8569-861X
  • Iturbe, David|||0000-0002-5241-266X
  • Mora Cuesta, Víctor Manuel|||0000-0002-8161-0462
  • Ortego-Centeno, Norberto|||0000-0003-2325-0937
  • Gómez, Nair Pérez
  • Mera-Varela, Antonio
  • Martínez Barrio, Julia
  • López Longo, Francisco Javier
  • Mijares, Verónica
  • Lera-Gómez, Leticia
  • Usetti, María Piedad
  • Laporta, Rosalía
  • Pérez González, Virginia Luz
  • Gafas, Alicia De Pablo
  • Alfranca González, María Aránzazu
  • Calvo Alén, Jaime|||0000-0001-9378-8412
  • Romero-Bueno, Fredeswinda
  • Sánchez Pernaute, Olga
  • Nuno, Laura
  • Bonilla, Gema
  • Balsa, Alejandro|||0000-0001-8070-7062
  • Hernández-González, Fernanda
  • Grafia, Ignacio
  • Prieto-González, Sergio|||0000-0003-3179-597X
  • Narváez, Javier|||0000-0002-1614-8064
  • Trallero Araguás, Ernesto|||0000-0003-3365-4521
  • Selva O'Callaghan, Albert|||0000-0003-2823-9761
  • Gualillo, Oreste|||0000-0002-7154-1328
  • Castañeda, Santos|||0000-0002-7748-853X
  • Cavagna, Lorenzo|||0000-0003-3292-1528
  • Cifrián, José Manuel|||0000-0003-3682-0142
  • Gonzalez-Gay, MA.|||0000-0002-7924-7406
MUC5B rs35705950 (G/T) is strongly associated with idiopathic pulmonary fibrosis (IPF) and also contributes to the risk of interstitial lung disease (ILD) in rheumatoid arthritis (RA-ILD) and chronic hypersensitivity pneumonitis (CHP). Due to this, we evaluated the implication of MUC5B rs35705950 in antisynthetase syndrome (ASSD), a pathology characterised by a high ILD incidence. 160 patients with ASSD (142 with ILD associated with ASSD [ASSD-ILD+]), 232 with ILD unrelated to ASSD (comprising 161 IPF, 27 RA-ILD and 44 CHP) and 534 healthy controls were genotyped. MUC5B rs35705950 frequency did not significantly differ between ASSD-ILD+ patients and healthy controls nor when ASSD patients were stratified according to the presence/absence of anti Jo-1 antibodies or ILD. No significant differences in MUC5B rs35705950 were also observed in ASSD-ILD+ patients with a usual interstitial pneumonia (UIP) pattern when compared to those with a non-UIP pattern. However, a statistically significant decrease of MUC5B rs35705950 GT, TT and T frequencies in ASSD-ILD+ patients compared to patients with ILD unrelated to ASSD was observed. In summary, our study does not support a role of MUC5B rs35705950 in ASSD. It also indicates that there are genetic differences between ILD associated with and that unrelated to ASSD.
RUO. Repositorio Institucional de la Universidad de Oviedo
Publication Artículo científico (JournalArticle)

Angiogenic T cells: potential biomarkers for the early diagnosis of interstitial lung disease in autoimmune diseases?

  • Pulito Cueto, V.
  • Remuzgo Martínez, S.
  • Genre, F.
  • Atienza Mateo, B.
  • Mora Cuesta, V. M.
  • Iturbe Fernández, D.
  • Lera Gómez, L.
  • Rodríguez Carrio, Javier|||0000-0002-0011-5102
V.P.-C. and S.R.-M. are supported by funds of RETICS Program [RD16/0012/0009, Instituto de Salud Carlos III (ISCIII), co-funded by European Regional Development Fund (ERDF); FG is supported by funds of the RICORS Program (RD21/0002/0025) from ISCIII, co-funded by the European Union; OG is staff personnel of Xunta de Galicia (Servizo Galego de Saude (SERGAS) through a research-staff stabilization contract (ISCIII/SERGAS) and his work is funded by ISCIII and ERDF [RD16/0012/0014 (RIER) and PI17/00409]. He is the beneficiary of project funds from the Research Executive Agency of the European Union in the framework of MSCA-RISE Action of the H2020 Programme, project 734899—Olive-Net. RL-M is a recipient of a Miguel Servet type II Program fellowship from ISCIII, co-funded by the European Social Fund, ‘Investing in your future’ (CPII21/00004)., Pulito-Cueto V, Remuzgo-Martínez S, Genre F, Atienza-Mateo B, Mora-Cuesta VM, Iturbe-Fernández D, Lera-Gómez L, Rodriguez-Carrio J, Prieto-Peña D, Portilla V, Blanco R, Corrales A, Gualillo O, Cifrián JM, López-Mejías R, González-Gay MA